Amyloid beta plaques Inhibitors
1 drugsAbout Amyloid beta plaques
Amyloid beta plaques are extracellular deposits primarily composed of Amyloid beta (Aβ) peptides, formed through the cleavage of the amyloid precursor protein (APP). These plaques are a hallmark of Alzheimer's disease and a critical target in central nervous system (CNS) drug development. Their presence is strongly correlated with neuronal dysfunction and cognitive decline.
Targeting Amyloid beta plaques is motivated by their strong association with Alzheimer's. Currently, there is no genetic evidence directly linking this target to disease. Developing therapies that modulate Aβ plaque formation or clearance could offer a promising avenue for treating this neurodegenerative disease.
The target has one FDA-approved diagnostic drug, AMYVID, a small molecule used for detecting plaques. AVID Radiopharmaceuticals Inc. is the sole company with an approved drug for this target, which is indicated for CNS disorders.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Helicobacter Pylori Infection with only 1 trials.
Top Amyloid beta plaques Drugs
AVID Radiopharmaceuticals Inc. is the only company with an approved drug targeting Amyloid beta plaques.
The market's low competition presents an opportunity for new entrants with innovative therapeutic approaches.
Amyloid beta plaques Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Amyloid beta plaques, using small molecule modality.
Exploring alternative modalities like antibodies or gene therapies could offer a competitive advantage.
Amyloid beta plaques Clinical Trials 6 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 | 100% |
| Phase 2 | 2 | 1 | 0 | 1 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 0 | 1 | 0 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Amyloid beta plaques Drug Approval Timeline (2012 - 2012)
The first and only drug, AMYVID, was approved in 2012.
The stagnant approval timeline indicates a potential saturation or challenges in developing effective plaque-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (13 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 13 clinical trials targeting Amyloid beta plaques.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities